vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and ThredUp Inc. (TDUP). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $79.7M, roughly 1.1× ThredUp Inc.). On growth, ThredUp Inc. posted the faster year-over-year revenue change (18.5% vs 17.7%). ThredUp Inc. produced more free cash flow last quarter ($-3.2M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 11.1%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
ThredUp Inc. is an American company that operates an online resale platform specializing in the sale of second-hand clothing, footwear, and accessories. Founded in 2009 and headquartered in Oakland, California, it has established itself as one of the leading resale fashion marketplaces.
IOVA vs TDUP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $79.7M |
| Net Profit | — | $-5.6M |
| Gross Margin | 67.4% | 79.6% |
| Operating Margin | -84.7% | -8.4% |
| Net Margin | — | -7.0% |
| Revenue YoY | 17.7% | 18.5% |
| Net Profit YoY | — | 74.3% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $79.7M | ||
| Q3 25 | $67.5M | $82.2M | ||
| Q2 25 | $60.0M | $77.7M | ||
| Q1 25 | $49.3M | $71.3M | ||
| Q4 24 | $73.7M | $67.3M | ||
| Q3 24 | $58.6M | $61.5M | ||
| Q2 24 | $31.1M | $66.7M | ||
| Q1 24 | $715.0K | $64.5M |
| Q4 25 | — | $-5.6M | ||
| Q3 25 | $-91.3M | $-4.2M | ||
| Q2 25 | $-111.7M | $-5.2M | ||
| Q1 25 | $-116.2M | $-5.2M | ||
| Q4 24 | — | $-21.7M | ||
| Q3 24 | $-83.5M | $-24.8M | ||
| Q2 24 | $-97.1M | $-14.0M | ||
| Q1 24 | $-113.0M | $-16.6M |
| Q4 25 | 67.4% | 79.6% | ||
| Q3 25 | 43.0% | 79.4% | ||
| Q2 25 | 5.5% | 79.5% | ||
| Q1 25 | -0.8% | 79.1% | ||
| Q4 24 | 68.7% | 80.4% | ||
| Q3 24 | 46.2% | 79.3% | ||
| Q2 24 | -0.8% | 78.8% | ||
| Q1 24 | — | 80.1% |
| Q4 25 | -84.7% | -8.4% | ||
| Q3 25 | -140.7% | -5.3% | ||
| Q2 25 | -189.8% | -6.8% | ||
| Q1 25 | -245.8% | -7.6% | ||
| Q4 24 | -117.5% | -12.1% | ||
| Q3 24 | -152.1% | -17.0% | ||
| Q2 24 | -327.6% | -14.4% | ||
| Q1 24 | -16464.6% | -19.2% |
| Q4 25 | — | -7.0% | ||
| Q3 25 | -135.3% | -5.2% | ||
| Q2 25 | -186.2% | -6.7% | ||
| Q1 25 | -235.5% | -7.3% | ||
| Q4 24 | — | -32.3% | ||
| Q3 24 | -142.7% | -40.3% | ||
| Q2 24 | -312.2% | -20.9% | ||
| Q1 24 | -15800.8% | -25.7% |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | $-0.33 | $-0.04 | ||
| Q1 25 | $-0.36 | $-0.04 | ||
| Q4 24 | $-0.24 | $-0.19 | ||
| Q3 24 | $-0.28 | $-0.22 | ||
| Q2 24 | $-0.34 | $-0.13 | ||
| Q1 24 | $-0.42 | $-0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $38.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $59.2M |
| Total Assets | $913.2M | $167.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $38.6M | ||
| Q3 25 | $300.8M | $46.2M | ||
| Q2 25 | $301.2M | $41.0M | ||
| Q1 25 | $359.7M | $41.1M | ||
| Q4 24 | $323.8M | $31.9M | ||
| Q3 24 | $397.5M | $43.7M | ||
| Q2 24 | $412.5M | $44.8M | ||
| Q1 24 | $356.2M | $50.1M |
| Q4 25 | $698.6M | $59.2M | ||
| Q3 25 | $702.3M | $59.1M | ||
| Q2 25 | $698.5M | $60.2M | ||
| Q1 25 | $767.9M | $56.1M | ||
| Q4 24 | $710.4M | $56.3M | ||
| Q3 24 | $773.5M | $69.3M | ||
| Q2 24 | $768.5M | $86.5M | ||
| Q1 24 | $680.0M | $93.5M |
| Q4 25 | $913.2M | $167.2M | ||
| Q3 25 | $904.9M | $172.5M | ||
| Q2 25 | $907.4M | $173.6M | ||
| Q1 25 | $966.7M | $172.5M | ||
| Q4 24 | $910.4M | $171.2M | ||
| Q3 24 | $991.1M | $214.9M | ||
| Q2 24 | $964.3M | $231.2M | ||
| Q1 24 | $869.8M | $244.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $-1.5M |
| Free Cash FlowOCF − Capex | $-61.9M | $-3.2M |
| FCF MarginFCF / Revenue | -71.3% | -4.0% |
| Capex IntensityCapex / Revenue | 10.7% | 2.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $180.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $-1.5M | ||
| Q3 25 | $-78.7M | $6.0M | ||
| Q2 25 | $-67.4M | $344.0K | ||
| Q1 25 | $-103.7M | $5.7M | ||
| Q4 24 | $-73.3M | $663.0K | ||
| Q3 24 | $-59.0M | $3.3M | ||
| Q2 24 | $-98.4M | $-5.0M | ||
| Q1 24 | $-122.3M | $1.4M |
| Q4 25 | $-61.9M | $-3.2M | ||
| Q3 25 | $-89.5M | $2.4M | ||
| Q2 25 | $-74.9M | $-2.9M | ||
| Q1 25 | $-109.9M | $3.9M | ||
| Q4 24 | $-77.5M | $-1.8M | ||
| Q3 24 | $-61.3M | $1.2M | ||
| Q2 24 | $-98.9M | $-5.8M | ||
| Q1 24 | $-126.5M | $267.0K |
| Q4 25 | -71.3% | -4.0% | ||
| Q3 25 | -132.7% | 2.9% | ||
| Q2 25 | -124.9% | -3.8% | ||
| Q1 25 | -222.8% | 5.5% | ||
| Q4 24 | -105.1% | -2.7% | ||
| Q3 24 | -104.6% | 2.0% | ||
| Q2 24 | -317.9% | -8.7% | ||
| Q1 24 | -17685.3% | 0.4% |
| Q4 25 | 10.7% | 2.2% | ||
| Q3 25 | 16.1% | 4.4% | ||
| Q2 25 | 12.4% | 4.2% | ||
| Q1 25 | 12.6% | 2.5% | ||
| Q4 24 | 5.7% | 3.7% | ||
| Q3 24 | 3.9% | 3.5% | ||
| Q2 24 | 1.4% | 1.3% | ||
| Q1 24 | 583.4% | 1.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
TDUP
Segment breakdown not available.
